



EUPATI: European Patient's Academy on Therapeutic Innovation

Maria Mavris
Therapeutic Development Director
EURORDIS

European Patients' Academy (EUPATI)



- ▶ Launched in Feb '12, runs for 5 years, 29 consortium members, PPP of EU Commission and EFPIA
- ▶ will develop and disseminate objective, credible, correct and up-to-date public knowledge about medicines R&D
- ▶ will build competencies & expert capacity among patients & public
- ▶ will facilitate patient involvement in R&D to support academia, authorities, industry and ethics committees



Topics of the Patients' Academy

- 1. Medicines development process from research to approval**
- 2. Personalised and predictive medicine**
- 3. Drug safety and risk/benefit assessment of medicines**
- 4. Pharmaco-economics and health technology assessment**
- 5. Design and objectives of clinical trials (& roles of stakeholders)**
- 6. Patients roles & responsibilities in medicines development**

...and *NOT*:
develop indication- or
therapy-specific
information!

Reflecting European diversity: 7 languages




- **7 most frequently spoken languages:**

English, French, German, Spanish, Polish, Russian, Italian

- **Serving 12 European countries:**

UK, Ireland, Malta, France, Luxemburg, the francophone Belgium, Germany, Austria, Switzerland, Spain, Italy and Poland, plus Russian-speaking population in CEE

Audiences: advocacy leaders and the public at large



EUPATI Certificate Training Programme



Patient Ambassadors in committees, HTA agencies, industry, regulatory bodies, academia etc

Patient Journalists raising awareness

Patient Trainers for patient communities and networks.

**100
patient
advocates**

EUPATI Educational Toolbox



Educational tools for patient advocates (print, slide shows, eLearning, webinars, videos) for patient advocates

**12.000
patient
advocates**

EUPATI Internet Library



Patients & lay public at large, e.g. on specific aspects of the development process of medicines for patients with low (health) literacy.

**100.000
individuals**

Strong consortium & strong governance



- **Leading pan-EU patient umbrella groups**
- **Strong impetus from key academic partners and research organisations**
- **Industry expertise in medicines R&D**
- **Advisory bodies & codes committed to ensure independence and good governance**
 - EMA, Swissmedic, MHRA, BfArM
 - Key experts in bioethics, genetics, HTA, economics, evidence based med, patient advocacy



More Information on www.patientsacademy.eu



Web:
www.patientsacademy.eu

Twitter:
[@eupatients](https://twitter.com/eupatients)